

101584283

AP3 Rec'd PCT/PTO 26 JUN 2008

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q95705

Akio HAYASHI et al.

Appln. No.: National Stage of PCT/JP2004/019241

Confirmation No.: Unassigned

Group Art Unit: Unassigned

Filed: June 26, 2006

Examiner: Unassigned

For: HIGHLY ACTIVE LYSOPHOSPHATIDIC ACID AND METHOD OF SCREENING  
THEREWITH

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, along with a copy of the corresponding Communication from a Foreign Patent Office, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office

10/584283  
AP3 Rec'd PCT/PTO 26 JUN 2006

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: National Stage of PCT/JP2004/019241

Page 2

Action after filing a request for continued examination (RCE) under §1.114, and therefore, no

Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents (International Search Report for PCT/JP2004/019241 dated February 8, 2005), together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

*John Callahan Reg. No. 32,607*  
for Mark Boland  
Registration No. 32,197

SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE  
23373  
CUSTOMER NUMBER

Date: June 26, 2006

AD2 Rec'd PCT/PTO 26 JUN 2011  
TOP SECRET PTO/SB/08 A & B (08-03)

10/584285

U.S. PATENT AND TRADEMARK OFFICE PTO/SB/08 A & B (08-03)

**Complete if Known**

**Substitute for Form 1449 A & B/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet

1

of

1

Application Number	PCT/JP2004/019241
Confirmation Number	Unassigned
Filing Date	June 26, 2006
First Named Inventor	Akio HAYASHI
Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number Q95705

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
/SK/		KOJI BANDOH, "Lysophosphatidic acid receptors of the EDG family are differentially activated by LPA species", FEBS Letters, Vol. 478, pages 159 to 165, (July 28, 2000)	

<b>Examiner Signature</b>	/Sudhakar Katakam/	<b>Date Considered</b>	11/16/2009
---------------------------	--------------------	------------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.

<sup>6</sup> Applicant is to indicate here if English language Translation is attached.